Section I · Clinical

Clinical Archive.

Stem cell and exosome clinical trials, organized case by case. Each entry covers trial design, results, clinical significance, and context.

Trial status (recruiting / active / completed / terminated) is synced daily from the ClinicalTrials.gov API.

UC-MSC Injection — Umbilical Cord MSC for Interstitial Lung Disease, Phase 1
—
2026.05.12 Clinical PHASE 1UC-MSC
not-yet-recruiting
SECRET-OA — UC-MSC Secretome for Knee Osteoarthritis Pain and Function, Phase 2/3
—
2026.05.12 Clinical PHASE 2 3UC-MSC
not-yet-recruiting
Rincell-1 — Otic Neural Progenitors Combined with Cochlear Implant, First-in-Human Phase 1/2
—
2026.05.12 Clinical PHASE 1 2
not-yet-recruiting
RepCOPDiPS — iPSC-Based Bronchial Epithelial Repair Model for COPD
—
2026.05.12 Clinical NA
recruiting
NSC-EVs — Neural Stem Cell-Derived Exosomes for Early-Onset Alzheimer's Disease, Phase 1
—
2026.05.12 Clinical PHASE 1NSC
not-yet-recruiting
NouvNeu001 — Human Dopaminergic Progenitor Cells for Parkinson's Disease, Phase 1/2
—
2026.05.12 Clinical PHASE 1 2
recruiting
MSC Gel — Mesenchymal Stem Cell Gel for Burn Wound Treatment
—
2026.05.12 Clinical NA
recruiting
hUCMSC-EVs — Umbilical Cord MSC-Derived Extracellular Vesicles for Interstitial Lung Disease, Phase 1
—
2026.05.12 Clinical PHASE 1UC-MSC
not-yet-recruiting
HiCM-188 — iPSC-Derived Cardiomyocytes for Advanced Heart Failure, Phase 3
—
2026.05.12 Clinical PHASE 3iPSC
recruiting
EXO-DEX-SNHL — Dexamethasone-Loaded Exosomes for Intratympanic Drug Delivery in Acute Sensorineural Hearing Loss
—
2026.05.12 Clinical NAUC-MSC
recruiting
ExoFlo — Bone Marrow MSC Exosomes for Inflammatory and Respiratory Indications, Phase 2/3
The most advanced late-stage clinical trial among exosome-based therapeutics. Targeting moderate-to-severe COVID-19 ARDS.
2025.09.01 Clinical PHASE 2 3MSC-Exo
active
WJ-MSC for Chronic Complete Spinal Cord Injury, Phase I — Kaplan et al.
Safety and motor function assessment of intrathecal WJ-MSC administration in patients with chronic complete spinal cord injury.
2025.06.15 Clinical PHASE 1WJ-MSC
active
Laromestrocel — Allogeneic Bone Marrow MSC for Mild Alzheimer's Disease, Phase 2a
No ARIA (amyloid-related imaging abnormalities) observed. Signals of attenuated cognitive decline and brain atrophy at 9 months.
2025.03.10 Clinical PHASE 2ABM-MSC
completed
Wharton's Jelly MSC for Knee Osteoarthritis — Polish Multi-Centre Phase I/II
Single ultrasound-guided intra-articular injection of 10 million WJ-MSCs targeting knee, hip, and shoulder OA.
2024.12.31 Clinical PHASE 1 2WJ-MSC
active
ahaMSCs-Exos — Intranasal Exosome Delivery for Alzheimer's Disease Phase I/II
Intranasal administration bypasses the BBB. No adverse events reported; cognitive improvement on ADAS-cog observed in the mid-dose cohort.
2023.10.20 Clinical PHASE 1 2AD-MSC-Exo
completed